Illumina Inc
Change company Symbol lookup
Select an option...
ILMN Illumina Inc
HEI.A HEICO Corp
EVRI Everi Holdings Inc
AY Atlantica Sustainable Infrastructure PLC
AUMC Auryn Mining Corp
UI Ubiquiti Inc
AMRN Amarin Corporation PLC
FFBC First Financial Bancorp
BAC Bank of America Corp
DSI iShares MSCI KLD 400 Social ETF
Go

Health Care : Life Sciences Tools & Services | Mid Cap Blend
Company profile

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Core Illumina products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. GRAIL is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Customers use its platforms to perform whole genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes. The Company's BeadArray technology produces arrays that can perform many assays simultaneously. Customers use its array-based genotyping consumables for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.

Price
Delayed
$192.34
Day's Change
-8.95 (-4.45%)
Bid
--
Ask
--
B/A Size
--
Day's High
208.29
Day's Low
191.20
Volume
(Heavy Day)

Today's volume of 3,598,936 shares is on pace to be much greater than ILMN's 10-day average volume of 1,699,574 shares.

3,598,936

Company Profile

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Core Illumina products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. GRAIL is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Customers use its platforms to perform whole genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes. The Company's BeadArray technology produces arrays that can perform many assays simultaneously. Customers use its array-based genotyping consumables for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
6.37x
Price/Book (MRQ)
2.86x
Price/Cash Flow (TTM)
93.76x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

August 2022
Current Month
4.4M
Previous Month
3.5M
Percent of Float
2.79%
Days to Cover
2.9134 Days

Share Information

ILMN is in a share class of common stock
Float
156.6M
Shares Outstanding
157.1M
Institutions Holding Shares
1,340
87.22%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • John Wendell Thompson
  • Francis A. deSouzaPres.
  • Aimee L. Hoyt
  • Alex Aravanis
  • Carissa RollinsCIO

Address

Insider Trading

During the most recent quarter, 6K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.